Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $18.65 billion. The enterprise value is $22.45 billion.
| Market Cap | 18.65B |
| Enterprise Value | 22.45B |
Important Dates
The last earnings date was Thursday, August 6, 2026.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 59.70 million shares outstanding. The number of shares has decreased by -1.73% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 59.70M |
| Shares Change (YoY) | -1.73% |
| Shares Change (QoQ) | -3.36% |
| Owned by Insiders (%) | 1.22% |
| Owned by Institutions (%) | 57.44% |
| Float | 58.95M |
Valuation Ratios
The trailing PE ratio is 23.67 and the forward PE ratio is 18.82.
| PE Ratio | 23.67 |
| Forward PE | 18.82 |
| PS Ratio | 4.52 |
| Forward PS | 3.76 |
| PB Ratio | 3.13 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 21.46 |
| P/OCF Ratio | 20.93 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.61, with an EV/FCF ratio of 25.84.
| EV / Earnings | 28.49 |
| EV / Sales | 5.43 |
| EV / EBITDA | 19.61 |
| EV / EBIT | 20.94 |
| EV / FCF | 25.84 |
Financial Position
The company has a current ratio of 2.46, with a Debt / Equity ratio of 0.89.
| Current Ratio | 2.46 |
| Quick Ratio | 2.44 |
| Debt / Equity | 0.89 |
| Debt / EBITDA | 4.61 |
| Debt / FCF | 6.07 |
| Interest Coverage | 3.99 |
Financial Efficiency
Return on equity (ROE) is 14.00% and return on invested capital (ROIC) is 12.07%.
| Return on Equity (ROE) | 14.00% |
| Return on Assets (ROA) | 8.79% |
| Return on Invested Capital (ROIC) | 12.07% |
| Return on Capital Employed (ROCE) | 9.42% |
| Weighted Average Cost of Capital (WACC) | 7.23% |
| Revenue Per Employee | $1.32M |
| Profits Per Employee | $252,645 |
| Employee Count | 3,119 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 18.58 |
Taxes
In the past 12 months, Genmab has paid $118.00 million in taxes.
| Income Tax | 118.00M |
| Effective Tax Rate | 13.02% |
Stock Price Statistics
The stock price has increased by +43.44% in the last 52 weeks. The beta is 0.69, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | +43.44% |
| 50-Day Moving Average | 27.74 |
| 200-Day Moving Average | 29.01 |
| Relative Strength Index (RSI) | 70.59 |
| Average Volume (20 Days) | 2,113,791 |
Short Selling Information
The latest short interest is 7.56 million, so 1.25% of the outstanding shares have been sold short.
| Short Interest | 7.56M |
| Short Previous Month | 8.33M |
| Short % of Shares Out | 1.25% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.62 |
Income Statement
In the last 12 months, Genmab had revenue of $4.13 billion and earned $788.00 million in profits. Earnings per share was $1.27.
| Revenue | 4.13B |
| Gross Profit | 3.84B |
| Operating Income | 1.33B |
| Pretax Income | 906.00M |
| Net Income | 788.00M |
| EBITDA | 1.15B |
| EBIT | 1.07B |
| Earnings Per Share (EPS) | $1.27 |
Balance Sheet
The company has $1.51 billion in cash and $5.27 billion in debt, with a net cash position of -$3.76 billion or -$63.03 per share.
| Cash & Cash Equivalents | 1.51B |
| Total Debt | 5.27B |
| Net Cash | -3.76B |
| Net Cash Per Share | -$63.03 |
| Equity (Book Value) | 5.96B |
| Book Value Per Share | 99.78 |
| Working Capital | 1.66B |
Cash Flow
In the last 12 months, operating cash flow was $891.00 million and capital expenditures -$22.00 million, giving a free cash flow of $869.00 million.
| Operating Cash Flow | 891.00M |
| Capital Expenditures | -22.00M |
| Depreciation & Amortization | 43.00M |
| Net Borrowing | 5.36B |
| Free Cash Flow | 869.00M |
| FCF Per Share | $14.56 |
Margins
Gross margin is 93.03%, with operating and profit margins of 32.29% and 19.08%.
| Gross Margin | 93.03% |
| Operating Margin | 32.29% |
| Pretax Margin | 21.93% |
| Profit Margin | 19.08% |
| EBITDA Margin | 27.72% |
| EBIT Margin | 25.95% |
| FCF Margin | 21.04% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.73% |
| Shareholder Yield | 1.73% |
| Earnings Yield | 4.22% |
| FCF Yield | 4.66% |
Analyst Forecast
The average price target for Genmab is $38.84, which is 23.93% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $38.84 |
| Price Target Difference | 23.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 20.10% |
| EPS Growth Forecast (3Y) | 13.91% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 2.91 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.91 |
| Piotroski F-Score | 4 |